Molnupiravir, has been developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics (MK-4482/EIDD-2801). Molnupiravir has been in development as a broad-spectrum antiviral for approximately 10 years. It was first tested as an Ebola drug in Liberia’s 2016–2017 outbreak. Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA.
This product is now available for research purposes only in limited quantities.
Cancer Research and Antivirals
API's & Drug Standards
|Appearance||White to off-white powder|
|MDL Number||Request if not shown|
Send us your enquiry for Molnupiravir. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Molnupiravir email us and we will include your contribution on the website.